EA201692045A1 - Производное фенантролинфосфоновой кислоты и способ его получения и применения - Google Patents
Производное фенантролинфосфоновой кислоты и способ его получения и примененияInfo
- Publication number
- EA201692045A1 EA201692045A1 EA201692045A EA201692045A EA201692045A1 EA 201692045 A1 EA201692045 A1 EA 201692045A1 EA 201692045 A EA201692045 A EA 201692045A EA 201692045 A EA201692045 A EA 201692045A EA 201692045 A1 EA201692045 A1 EA 201692045A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- preparation
- phenanthroliphosphone
- acid
- derivative
- application
- Prior art date
Links
- 239000002253 acid Substances 0.000 title 1
- 102000008186 Collagen Human genes 0.000 abstract 2
- 108010035532 Collagen Proteins 0.000 abstract 2
- 229920001436 collagen Polymers 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 abstract 1
- 102000004079 Prolyl Hydroxylases Human genes 0.000 abstract 1
- 108010043005 Prolyl Hydroxylases Proteins 0.000 abstract 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/60—Quinoline or hydrogenated quinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
- C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Настоящее изобретение относится к новому соединению фенантролинфосфоновой кислоты и его фармацевтической соли, а также к применению соединения и его фармацевтической соли в качестве ингибиторов коллагенпролилгидроксилазы в получении лекарственных средств для предупреждения или лечения заболевания, связанного с коллагенпролил-4-гидроксила.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410142608.8A CN104974187A (zh) | 2014-04-10 | 2014-04-10 | 菲罗啉类衍生物及其制备方法和应用 |
PCT/CN2015/076273 WO2015154716A1 (zh) | 2014-04-10 | 2015-04-10 | 菲罗啉膦酸类衍生物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201692045A1 true EA201692045A1 (ru) | 2017-05-31 |
EA030709B1 EA030709B1 (ru) | 2018-09-28 |
Family
ID=54271195
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201692045A EA030709B1 (ru) | 2014-04-10 | 2015-04-10 | Производное фенантролинфосфоновой кислоты и способ его получения и применения |
Country Status (9)
Country | Link |
---|---|
US (1) | US10072035B2 (ru) |
EP (1) | EP3130593B1 (ru) |
JP (1) | JP6545254B2 (ru) |
KR (1) | KR102369908B1 (ru) |
CN (2) | CN104974187A (ru) |
CA (1) | CA2944805C (ru) |
EA (1) | EA030709B1 (ru) |
SG (1) | SG11201608422VA (ru) |
WO (1) | WO2015154716A1 (ru) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108863797B (zh) * | 2018-07-02 | 2021-01-15 | 吉首大学 | 一类3-(取代/非取代苯基)-3-羟基丙酰氧肟酸的制备方法 |
CN114958927A (zh) * | 2021-02-22 | 2022-08-30 | 尚科生物医药(上海)有限公司 | 一种制备(s)-1-(3-氯苯基)-1,3-丙二醇的方法 |
CN113072585B (zh) * | 2021-04-02 | 2023-11-10 | 厦门市博瑞来医药科技有限公司 | 手性芳基膦酸环二酯及其衍生物的制备 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3524846A (en) | 1967-06-02 | 1970-08-18 | Syntex Corp | Process for the didealkylation of phosphonate esters |
US6011021A (en) * | 1996-06-17 | 2000-01-04 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using naaladase inhibitors |
JP2003522093A (ja) * | 1997-10-24 | 2003-07-22 | ファイブロゲン インコーポレイテッド | フェナントロリン誘導体 |
US5916898A (en) * | 1997-10-24 | 1999-06-29 | Zeneca Limited | Phenanthroline derivatives |
PT1474425E (pt) * | 2002-01-07 | 2006-09-29 | Eisai Co Ltd | Desazapurinas e sua utilizacao |
US20100197687A1 (en) * | 2005-01-19 | 2010-08-05 | Benjamin Pelcman | Indoles Useful in the Treatment of Inflammation |
JP5362999B2 (ja) * | 2008-01-30 | 2013-12-11 | 九州電力株式会社 | 有機el素子およびジベンゾホスホールオキシド誘導体 |
JP5553275B2 (ja) * | 2010-03-31 | 2014-07-16 | 国立大学法人金沢大学 | 金属錯体およびこれを有効成分として含有する抗がん剤 |
WO2014043380A1 (en) | 2012-09-14 | 2014-03-20 | Ligand Pharmaceuticals Incorporated | Novel nucleotide prodrug compounds and use |
-
2014
- 2014-04-10 CN CN201410142608.8A patent/CN104974187A/zh active Pending
-
2015
- 2015-04-10 KR KR1020167031228A patent/KR102369908B1/ko active IP Right Grant
- 2015-04-10 SG SG11201608422VA patent/SG11201608422VA/en unknown
- 2015-04-10 CA CA2944805A patent/CA2944805C/en active Active
- 2015-04-10 EA EA201692045A patent/EA030709B1/ru not_active IP Right Cessation
- 2015-04-10 JP JP2017504230A patent/JP6545254B2/ja active Active
- 2015-04-10 US US15/302,568 patent/US10072035B2/en active Active
- 2015-04-10 EP EP15777566.9A patent/EP3130593B1/en active Active
- 2015-04-10 WO PCT/CN2015/076273 patent/WO2015154716A1/zh active Application Filing
- 2015-04-10 CN CN201580018088.2A patent/CN106661060B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN104974187A (zh) | 2015-10-14 |
EA030709B1 (ru) | 2018-09-28 |
WO2015154716A1 (zh) | 2015-10-15 |
KR102369908B1 (ko) | 2022-03-02 |
CA2944805A1 (en) | 2015-10-15 |
US10072035B2 (en) | 2018-09-11 |
CN106661060B (zh) | 2019-04-19 |
JP6545254B2 (ja) | 2019-07-17 |
CN106661060A (zh) | 2017-05-10 |
KR20160146791A (ko) | 2016-12-21 |
JP2017513934A (ja) | 2017-06-01 |
US20170029452A1 (en) | 2017-02-02 |
EP3130593A4 (en) | 2017-11-01 |
CA2944805C (en) | 2022-11-29 |
SG11201608422VA (en) | 2016-11-29 |
EP3130593B1 (en) | 2020-09-23 |
EP3130593A1 (en) | 2017-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201792354A1 (ru) | Композиции обетихолевой кислоты и способы применения | |
EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
EA201690930A1 (ru) | Композиции и способы модуляции фарнезоидных х-рецепторов | |
EA201500207A1 (ru) | Гетероароматические соединения в качестве ингибиторов втк | |
EA201791420A1 (ru) | Соединения триазолопиримидина и их применения | |
EA201790389A1 (ru) | Пирролопиримидиновые соединения, используемые в качестве агониста tlr7 | |
EA201791018A1 (ru) | Производные 6-амино-7-бицикло-7-деазапурина в качестве ингибиторов протеинкиназы | |
EA201691579A1 (ru) | Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b | |
EA201890899A1 (ru) | Модуляторы фарнезоидного x-рецептора | |
EA201691988A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
EA201690277A1 (ru) | Производные замещенного глиоксамидом пирроламида и их применение в качестве лекарственных средств для лечения гепатита b | |
EA201591591A1 (ru) | Соединения карбазола, применяемые в качестве ингибиторов бромодомена | |
EA201591166A1 (ru) | Ингибиторы аутотаксина | |
EA201400412A1 (ru) | ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ | |
EA201891063A1 (ru) | Производные дигидроимидазопиразинона, применимые в лечении рака | |
EA201692480A1 (ru) | Фармацевтическая композиция | |
EA201690406A1 (ru) | Селективные ингибиторы grp94 и способы их применения | |
EA201790599A1 (ru) | Соединения и композиции в качестве ингибиторов киназ | |
EA201691216A1 (ru) | Композиции линаклотида с замедленным высвобождением | |
EA201790576A1 (ru) | Спироциклические ингибиторы катепсина с | |
EA201691881A1 (ru) | Новые соединения | |
EA201692003A1 (ru) | Макроциклические производные пиримидина | |
EA201500931A1 (ru) | Производные пиридин-4-ила | |
EA201500851A1 (ru) | ЭСТРА-1,3,5(10),16-ТЕТРАЕН-3-КАРБОКСАМИДЫ ДЛЯ ИНГИБИРОВАНИЯ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ (AKR1C3) | |
EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC4A | Registration of transfer of a eurasian patent by assignment | ||
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM KG TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AZ BY KZ TJ |